Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer (ES-SCLC)

NCT05384015 is registered in ClinicalTrials.gov with Fundación GECP as lead sponsor.

NCT NCT05384015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05384015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Lead sponsor
Fundación GECP
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 7, 2022
Completion date
December 30, 2027
Enrollment
46 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer extensive stage